http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2538986-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2009-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b98721f90a8df894bb34875c2230cc5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_340743bb016e819e614faef014a26df8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7ac5ad6589759bbb12593c8cd2d68c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_639300ca3890df5fdead203acc39f3e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3010ae2113085597d98248954580942e |
| publicationDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2538986-C2 |
| titleOfInvention | IMIDAZOLYLDINONE DERIVATIVES AS B 11b-HSD1 INHIBITORS |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to compounds of formula , where R 1 represents hydroxyadamantyl, methoxycarbonyladamantyl, carboxyadamantyl, aminocarbonyladamantyl or aminocarbonylbicyclo[2.2.2]octanyl and where A represents CR 5 R 6 ; or phenyl, chlorobenzyl, benzyl, chlorophenylethyl, phenylethyl, difluorobenzyl, dichlorophenyl, trifluoromethylphenyl or difluorophenylethyl and where A represents CR 5 R 6 ; R 2 and R 3 together with nitrogen atom N* and carbon atom C*, which they are bount to, form group or ; R 4 represents hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, arylalkyl, arylalkoxygroup, arylalkoxyalkyl, hydroxyalkyl, aryl, heteroarylalkyl, heteroaryloxyalkyl, substituted aryl, substituted heteroarylalkyl or substituted heteroaryloxyalkyl, where substituted aryl, substituted heteroarylalkyl and substituted heteroaryloxyalkyl are substituted with 1-3 substituents, independently selected from alkyl, cycloalkyl, cyanogroup, halogen, halogenalkyl, hydroxygroup and alkoxygroup; R 5 represents hydrogen; R 6 represents hydrogen; as well as to their pharmaceutically acceptable salts and esters, which can be used as 11b-HSD1 inhibitors. n EFFECT: obtaining compounds which can be used as 11b-HSD1 inhibitors. n 9 cl, 1 tbl, 103 ex |
| priorityDate | 2008-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 463.